To general haemostasis - The evidence-based route

Pathophysiology of Haemostasis and Thrombosis

Volumn 32, Issue SUPPL. 1, 2002, Pages 47-52

  Erhardtsen, Elisabeth ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Anticoagulant therapy; Impaired liver function; Inhibitors; Safety; Thrombin; Traumata

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 7; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BERNARD SOULIER DISEASE; BLEEDING; BLEEDING TIME; CONFERENCE PAPER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; LIVER TRANSPLANTATION; PRIORITY JOURNAL; THROMBIN TIME; THROMBOCYTOPENIA; DRUG EFFECT; HEMOPHILIA A; IMMUNOLOGY; INJURY; LIVER DISEASE; REVIEW; THROMBOCYTE DISORDER;

ANTICOAGULANTS; BLOOD PLATELET DISORDERS; EVIDENCE-BASED MEDICINE; FACTOR VII; HEMOPHILIA A; HEMORRHAGE; HEMOSTASIS; HUMANS; LIVER DISEASES; RECOMBINANT PROTEINS; WOUNDS AND INJURIES;

EID: 19044372377     PISSN: 14248832     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057302     Document Type: Conference Paper

References (29)

1. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegaard J, Holm M, Hedner U: Recombinant factor VIIa (rFVIIa) reduces the bleeding time in patients with thrombocytopenia. Abstract presented at the 35th Annual Meeting of ASH, St. Louis, December 3-7, 1993.
2. Poon MC, Demers C, Jobin F, Wu JWY: Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood 1999;94:3951-3953.
3. Chuansumrit A, Treepongkaruna S, Phuapradit P: Successful invasive procedures in children with liver failure using recombinant factor VIIa. Haemophilia 2000;6:348.
4. Papatheodoridis GV, Chung S, Keshav S, Hardaker L, Pasi J, Burroughs AK: Recombinant factor VIIa is used in a Jehova's Witness with liver cirrhosis to correct prothrombin time, bleeding time, and thromboelastographic parameters, enabling safe percutaneous injection of hepatocellular carcinoma. Abstract presented at ISTH 1999.
5. Hedner U, Glazer S, Pingel K, Alberts KA, Blombäck M, Schulman S, Johnsson H: Successful use of recombinant factor VIIa in patient with severe haemophilia A during synivectomy. Lancet 1988;ii:1193.
6. Hedner U, Ingerslev J: Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998;19: 163-176.
7. Ingerslev J, Freidman D, Gastineau D, Gilchrist G, Johnsson H, Lucas G, McPherson J, Preston E, Scheibel E, Shuman M: Major surgery in haemophilic patients with inhibitors using recombinant factor VIIa. Haemostasis 1996;26(suppl 1):118-123.
8. Lusher JM, Ingerslev J, Roberts HR, Hedner U: Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998;9:119-128.
9. Shapiro AD, Gilchrist GS, Hoots WK, Cooper HA, Gastineau DA: Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778.
10. Glazer S, Hedner U, Falch JF: Clinical update on the use of recombinant factor VII. Adv Exp Med Biol 1995;386:163-174.
11. Lusher JM, Roberts HR, Davignon G, Joist JH, Smith H, Shapiro A, Laurian Y, Kasper CK, Mannucci PM: A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998;4:790-798.
12. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E: Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (NovoSeven) in haemophiliacs with inhibitors. Thromb Haemost 1998;80:912-918.
13. Hedner U, Erhardtsen E: Potential role for rFVIIa in transfusion medicine. Transfusion 2001; in press.
14. Kjalke M, Monroe DM, Hoffman M, Roberts HR, Hedner U, Ezban M: High-dose factor VIIa restores platelet activation and total thrombin generation in a model system mimicking hemophilia A or B conditions. Blood 1999;94(suppl 1):451a.
15. Kristensen J, Killander A, Hippe E, Helleberg C, Ellegaard J, Holm J, Kutti J, Mellqvist U-H, Johansson JE, Glazer S, Hedner U: Clinical Experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis 1996;26(suppl 1):159-164.
16. Vidarsson B, Ônundarson P: Recombinant factor VIIa for bleeding in refractory thrombocytopenia. Thromb Haemost 2001;83:634-635.
17. Attar S, Boyd D, Layne E, McLaughlin J, Mansberger AR, Cowley RA: Alterations in coagulation and fibrinolytic mechanisms in acute trauma. J Trauma 1969;9:939-965.
18. Essex D, Bluth M, Gloster E, Dimaio T, O'Neill P, Waly D, Kurtz R, Strauss R: Successful use of recombinant factor VIIa (rFVIIa) for trauma-associated massive hemorrhage. Blood 2000;96:268a.
19. Martinowitz U, Kenet G, Onaca N, Luboshitz J, Amit J, Heim M: New treatment of uncontrolled hemorrhage in trauma/surgical patients: Induction of local hypercoagulation. Abstract presented at the 60th Annual Meeting of the American Association for the Surgery of Trauma, San Antonio, USA, October 2000.
20. Kenet G, Walden R, Eldad A, Martinowitz U: Tratment of traumatic bleeding with recombinant factor VIIa. Lancet 1999;354:1879.
21. Kearon C, Hirsh J: Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1506-1511.
22. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD: Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota. Mayo Clin Proc 1995;70:725-733.
23. Erhardtsen E, Nony P, Dechavanne M, Ffrench P, Boissel JP, Hedner U: The effect of recombinant factor VIIa (NovoSeven(TM)) in healthy volunteers receiving accnocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 1998;9:741-748.
24. Berntorp E, Stigendal L, Lethagen S, Olofsson L, Hedner U: NovoSeven (R) in warfarin-treated patients. Blood Coagul Fibrinolysis 2000;11:S113-S115.
25. Deveras RAE, Kessler CM: Recombinant factor VIIa (rFVIIa) successfully and rapidly corrects the excessively high international normalized ratios (INR) and prothrombin times induced by warfarin. Blood 2000;96:638a.
26. Paramo JA, Rocha E: Hemostasis in advanced liver disease. Semin Thromb Hemost 1993;19: 84-190.
27. Rapaport SI: Coagulation problems in liver disease. Blood Coagul Fibrinolysis 2000;11:S69-S74.
28. Bernstein DE, Jeffers L, Erhardtsen E, Reddy KR, Glazer S, Squiban P, Bech R, Hedner U, Schiff ER: Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 1997;113: 1930-1937.
29. Jeffers L, Balart L, Erhardtsen E, Chalasani N, Ortiz A, Pyrsopoulos N: Efficacy and safety of rFVIIa in patients with severe coagulopathy undergoing laparoscopic liver biopsy. Blood 1999;94(suppl 1):236a.